JP2011523415A - 新規な二重標的化抗腫瘍複合体 - Google Patents

新規な二重標的化抗腫瘍複合体 Download PDF

Info

Publication number
JP2011523415A
JP2011523415A JP2011509923A JP2011509923A JP2011523415A JP 2011523415 A JP2011523415 A JP 2011523415A JP 2011509923 A JP2011509923 A JP 2011509923A JP 2011509923 A JP2011509923 A JP 2011509923A JP 2011523415 A JP2011523415 A JP 2011523415A
Authority
JP
Japan
Prior art keywords
formula
absent
compound
cyclic peptide
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011509923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011523415A5 (https=
Inventor
アルマ・ダル・ポッツォ
エミリアノ・エスポージト
ミンホン・ニ
セルジオ・ペンコ
クラウディオ・ピサノ
マッシモ・カストーリナ
ロレダーナ・ヴェッシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2011523415A publication Critical patent/JP2011523415A/ja
Publication of JP2011523415A5 publication Critical patent/JP2011523415A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011509923A 2008-05-20 2009-05-11 新規な二重標的化抗腫瘍複合体 Pending JP2011523415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156575 2008-05-20
EP08156575.6 2008-05-20
PCT/EP2009/055653 WO2009141240A1 (en) 2008-05-20 2009-05-11 Novel dual targeting antitumoural conjugates

Publications (2)

Publication Number Publication Date
JP2011523415A true JP2011523415A (ja) 2011-08-11
JP2011523415A5 JP2011523415A5 (https=) 2012-06-28

Family

ID=39765065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509923A Pending JP2011523415A (ja) 2008-05-20 2009-05-11 新規な二重標的化抗腫瘍複合体

Country Status (16)

Country Link
US (1) US20110160147A1 (https=)
EP (1) EP2285396A1 (https=)
JP (1) JP2011523415A (https=)
KR (1) KR20110022594A (https=)
CN (1) CN102036676A (https=)
AR (1) AR071840A1 (https=)
AU (1) AU2009249795A1 (https=)
BR (1) BRPI0911978A2 (https=)
CA (1) CA2724562A1 (https=)
EA (1) EA201071326A1 (https=)
IL (1) IL208920A0 (https=)
MX (1) MX2010012320A (https=)
NZ (1) NZ588948A (https=)
TW (1) TW201004647A (https=)
WO (1) WO2009141240A1 (https=)
ZA (1) ZA201009036B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260382A (zh) * 2018-11-05 2021-08-13 拜耳医药股份有限公司 含整合素配体的细胞抑制性缀合物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
CA2770980A1 (en) 2009-07-15 2011-01-20 Roger Y. Tsien Peptides whose uptake in cells is controllable
CA2816041C (en) * 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CA2841249C (en) 2011-07-29 2023-09-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
EA031930B1 (ru) 2013-01-30 2019-03-29 Авелас Байосайенсиз, Инк. Молекула селективной доставки для визуализации злокачественной ткани
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10125124B2 (en) 2015-03-20 2018-11-13 Massachusetts Institute Of Technology Formation of macromolecules using iterative growth and related compounds
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002544242A (ja) * 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物
JP2008504235A (ja) * 2004-05-13 2008-02-14 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 細胞分裂阻害剤として７位にて環状ペプチドと接合したカンプトテシン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404650B2 (en) * 2005-10-28 2013-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating cancer with doxazolidine and prodrugs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002544242A (ja) * 1999-05-14 2002-12-24 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 酵素活性化抗腫瘍プロドラッグ化合物
JP2008504235A (ja) * 2004-05-13 2008-02-14 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 細胞分裂阻害剤として７位にて環状ペプチドと接合したカンプトテシン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5011001971; ＤＵＢＯＷＣＨＩＫ，　Ｇ．Ｍ．　ｅｔ　ａｌ．: '"ＣＡＴＨＥＰＳＩＮ　Ｂ-ＬＡＢＩＬＥ　ＤＩＰＥＰＴＩＤＥ　ＬＩＮＫＥＲＳ　ＦＯＲ　ＬＹＳＯＳＯＭＡＬ　ＲＥＬＥＡＳＥ　ＯＦ　ＤＯＸＯＲＵＢＩＣＩＮ　ＦＲＯＭ　ＩＮＴＥＲＮＡＬＩＺＩＮＧ　ＩＭＭＵＮＯ' ＢＩＯＣＯＮＪＵＧＡＴＥ　ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．１３，　Ｎｏ．４, 20020101, Ｐ．８５５-８６９ *
JPN5011001972; ＬＥＵ，　Ｙ．Ｌ．　ｅｔ　ａｌ: '"ＢＥＮＺＹＬ　ＥＴＨＥＲ-ＬＩＮＫＥＤ　ＧＬＵＣＵＲＯＮＩＤＥ　ＤＥＲＩＶＡＴＩＶＥ　ＯＦ　１０-ＨＹＤＲＯＸＹＣＡＭＰＴＯＴＨＥＣＩＮ　ＤＥＳＩＧＮＥＤ　ＦＯＲ　ＳＥＬＥＣＴＩＶＥ　ＣＡＭＰＴＯＴ' ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．５１，　Ｎｏ．６, 200803, Ｐ．１７４０-１７４６ *
JPN5011001973; ＤＡＬ　ＰＯＺＺＯ，　Ａ．　ｅｔ　ａｌ．: '"ＮＯＶＥＬ　ＴＵＭＯＲ-ＴＡＲＧＥＴＥＤ　ＰＥＰＴＩＤＥ-ＣＡＭＰＴＯＴＨＥＣＩＮ　ＣＯＮＪＵＧＡＴＥＳ：　ＳＹＮＴＨＥＳＩＳ　ＡＮＤ　ＢＩＯＬＯＧＩＣＡＬ　ＥＶＡＬＵＡＴＩＯＮ．"' ２９ＴＨ　ＥＵＲＯＰＥＡＮ　ＰＥＰＴＩＤＥ　ＳＹＭＰＯＳＩＵＭ , 20060908 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260382A (zh) * 2018-11-05 2021-08-13 拜耳医药股份有限公司 含整合素配体的细胞抑制性缀合物
JP2022506299A (ja) * 2018-11-05 2022-01-17 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート
JP7509768B2 (ja) 2018-11-05 2024-07-02 バイエル ファーマ アクチェンゲゼルシャフト インテグリンリガンドを有する新規な細胞増殖抑制コンジュゲート
CN113260382B (zh) * 2018-11-05 2024-09-13 拜耳医药股份有限公司 含整合素配体的细胞抑制性缀合物

Also Published As

Publication number Publication date
TW201004647A (en) 2010-02-01
CN102036676A (zh) 2011-04-27
EA201071326A1 (ru) 2011-06-30
MX2010012320A (es) 2010-12-01
NZ588948A (en) 2011-10-28
ZA201009036B (en) 2012-01-25
IL208920A0 (en) 2011-01-31
AU2009249795A1 (en) 2009-11-26
WO2009141240A1 (en) 2009-11-26
KR20110022594A (ko) 2011-03-07
US20110160147A1 (en) 2011-06-30
EP2285396A1 (en) 2011-02-23
BRPI0911978A2 (pt) 2019-09-24
AR071840A1 (es) 2010-07-21
CA2724562A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
AU2002306500C1 (en) Transporters comprising spaced arginine moieties
US20040161405A9 (en) Guanidinium transport reagents and conjugates
Dal Pozzo et al. Novel tumor-targeted RGD peptide–camptothecin conjugates: Synthesis and biological evaluation
Homma et al. Synthesis and optimization of hyaluronic acid–methotrexate conjugates to maximize benefit in the treatment of osteoarthritis
CA2286232A1 (en) Dna-binding pyrrole and imidazole polyamide derivatives
PL185762B1 (pl) Nowe peptydy stanowiące pochodne dolastatyny, ichzastosowanie w medycynie oraz kompozycja farmaceutyczna
AU2010244857A1 (en) High penetration prodrug compositions of peptides and peptide-related compounds
JP2021501201A (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
US10500286B2 (en) CCK2R-drug conjugates
EP1753776B1 (en) Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents
US11319341B2 (en) Immune-stimulating soluble doxorubicin-conjugated complex
JP2006520741A (ja) 生物医学的及び医学的使用のための新規な両親媒性（ａｍｐｉｐｈｉｌｉｃ）フッ素化炭化水素分子ベクター
JP2001514659A (ja) ドラスタチン−１５誘導体とタキサンとの併用
JP3939354B2 (ja) 抗腫瘍性ペプチド
WO1997010261A1 (fr) Derives peptidiques
CN101010103A (zh) 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物
HK1155363A (en) Novel dual targeting antitumoural conjugates
CA3208877A1 (en) Cryptophycin compounds and conjugates thereof
JP2007537243A (ja) ２０位にてインテグリンアンタゴニストと接合した７−ｔ−ブトキシイミノメチルカンプトテシン
TW202426031A (zh) ＥｐｈＡ２結合待定肽及包含其之組成物
Parente Diketopiperazines as scaffold for the synthesis of new compounds modulating protein-protein interactions and functions
HK1104047A (en) Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents
HK1107005A (en) Camptothecin derivatives conjugated in position 20 with integrin antagonists
FR2948571A1 (fr) Utilisation d'oligomeres mimes contraints de dipeptides et tripeptides en tant qu'agents de vectorisation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140428